Cardiovascular and metabolic disease
3 European H2020 organizations list this as part of their work — 1 as their primary capability.
Most active in this area
- UNIVERSITEIT MAASTRICHT
Dutch research university excelling in neuroscience, bioprinting, regenerative medicine, and AI-driven health innovation across 243 H2020 projects.
“CATCH ME (atrial fibrillation, €718K), AFib-TrainNet, SIRENE and MIRAGE (heart failure/ARVC microRNA therapies), plus obesity-focused projects in recent period.”
PrimaryNL243 projects - IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Greek biomedical research institute specializing in autoimmunity, inflammation, neuroscience, and multi-omics translational research under the Academy of Athens.
“Coordinated TO_AITION on immune-metabolic causes of cardiovascular disease, contributed to CoroPrevention, CaReSyAn, STRATEGY-CKD, and GALAXY.”
EL39 projects - LINKCARE HEALTH SERVICES SL
Barcelona digital health SME specialising in chronic disease management, personalised medicine, and care coordination technology.
“Contributed as a third-party partner to MOGLYNET (2015–2019), which addressed atherosclerosis treatment through modulation of glycolytic flux.”
SMEES2 projects